Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

USA - NASDAQ:VIR - US92764N1028 - Common Stock

6.27 USD
0 (0%)
Last: 10/21/2025, 8:00:02 PM
6.27 USD
0 (0%)
After Hours: 10/21/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, VIR scores 3 out of 10 in our fundamental rating. VIR was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. VIR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VIR has reported negative net income.
In the past year VIR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: VIR reported negative net income in multiple years.
In the past 5 years VIR reported 4 times negative operating cash flow.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

The Return On Assets of VIR (-46.14%) is comparable to the rest of the industry.
With a decent Return On Equity value of -58.07%, VIR is doing good in the industry, outperforming 62.55% of the companies in the same industry.
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

VIR's Gross Margin of 96.08% is amongst the best of the industry. VIR outperforms 95.13% of its industry peers.
VIR's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VIR has been increased compared to 1 year ago.
The number of shares outstanding for VIR has been increased compared to 5 years ago.
There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

VIR has an Altman-Z score of -0.04. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
VIR has a Altman-Z score (-0.04) which is in line with its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.04
ROIC/WACCN/A
WACC9.35%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 7.01 indicates that VIR has no problem at all paying its short term obligations.
VIR's Current ratio of 7.01 is fine compared to the rest of the industry. VIR outperforms 69.29% of its industry peers.
A Quick Ratio of 7.01 indicates that VIR has no problem at all paying its short term obligations.
VIR has a better Quick ratio (7.01) than 69.66% of its industry peers.
Industry RankSector Rank
Current Ratio 7.01
Quick Ratio 7.01
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

VIR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.73%.
The Revenue for VIR has decreased by -75.90% in the past year. This is quite bad
The Revenue has been growing by 55.74% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%

3.2 Future

Based on estimates for the next years, VIR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.23% on average per year.
Based on estimates for the next years, VIR will show a small growth in Revenue. The Revenue will grow by 3.82% on average per year.
EPS Next Y13.12%
EPS Next 2Y11.82%
EPS Next 3Y10.45%
EPS Next 5Y10.23%
Revenue Next Year-83.95%
Revenue Next 2Y-56.99%
Revenue Next 3Y-35.89%
Revenue Next 5Y3.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.82%
EPS Next 3Y10.45%

More info and screens

0

5. Dividend

5.1 Amount

VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (10/21/2025, 8:00:02 PM)

After market: 6.27 0 (0%)

6.27

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-24 2025-07-24/bmo
Earnings (Next)10-30 2025-10-30/amc
Inst Owners67.6%
Inst Owner Change-0.04%
Ins Owners1.12%
Ins Owner Change-0.33%
Market Cap871.03M
Analysts82.86
Price Target17.57 (180.22%)
Short Float %11.26%
Short Ratio9.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.87%
Min EPS beat(2)-9.48%
Max EPS beat(2)-4.26%
EPS beat(4)1
Avg EPS beat(4)-11.67%
Min EPS beat(4)-46.72%
Max EPS beat(4)13.76%
EPS beat(8)3
Avg EPS beat(8)1.33%
EPS beat(12)4
Avg EPS beat(12)48.76%
EPS beat(16)7
Avg EPS beat(16)213.56%
Revenue beat(2)0
Avg Revenue beat(2)-60.45%
Min Revenue beat(2)-65.06%
Max Revenue beat(2)-55.84%
Revenue beat(4)1
Avg Revenue beat(4)-31.9%
Min Revenue beat(4)-65.06%
Max Revenue beat(4)50.52%
Revenue beat(8)3
Avg Revenue beat(8)18.98%
Revenue beat(12)5
Avg Revenue beat(12)13.12%
Revenue beat(16)7
Avg Revenue beat(16)5.49%
PT rev (1m)0%
PT rev (3m)-2.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.09%
EPS NY rev (1m)0.36%
EPS NY rev (3m)-6.19%
Revenue NQ rev (1m)-6.09%
Revenue NQ rev (3m)-25.46%
Revenue NY rev (1m)-4.2%
Revenue NY rev (3m)-37.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.84
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-3.36
FCFYN/A
OCF(TTM)-3.29
OCFYN/A
SpS0.14
BVpS6.82
TBVpS6.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.08%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.21%
Cap/Sales 47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.01
Quick Ratio 7.01
Altman-Z -0.04
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
EPS Next Y13.12%
EPS Next 2Y11.82%
EPS Next 3Y10.45%
EPS Next 5Y10.23%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%
Revenue Next Year-83.95%
Revenue Next 2Y-56.99%
Revenue Next 3Y-35.89%
Revenue Next 5Y3.82%
EBIT growth 1Y-11.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.71%
EBIT Next 3Y7.47%
EBIT Next 5Y7.12%
FCF growth 1Y-13.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.4%
OCF growth 3YN/A
OCF growth 5YN/A